Subgroup analyses of LUX-Lung 3 and LUX-Lung 6 patients showed that afatinib* treatment resulted in significant progression-free survival (PFS) benefit versus chemotherapy in patients aged ≥65 years in the overall study populations (median PFS in LUX-Lung 3: 11.3 vs 8.2 months, hazard ratio [HR]=0.64; 95% confidence interval [CI]: 0.39–1.03; median PFS in LUX-Lung 6: 13.7 vs 4.1 months; HR=0.16; 95% CI: 0.07–0.39). Afatinib was also associated with PFS benefit in patients in this age group whose tumors had common epidermal growth factor receptor (EGFR) mutations (median PFS in LUX-Lung 3: 13.7 vs 8.2 months; HR=0.45; 95% CI: 0.26–0.78; median PFS in LUX-Lung 6: 13.7 vs 4.1 months; HR=0.15; 95% CI: 0.06–0.38).1 A significant increase in overall survival (OS) was also reported in elderly patients with del19 mutations in LUX-Lung 3 (median OS in this patient population: 41.5 vs 14.3 months; HR=0.39; 95% CI: 0.19–0.80).1 The safety profile of afatinib was generally similar across age groups, with a slightly higher incidence of Grade 3/4 treatment-related adverse events in elderly patients; however, this was also seen in the chemotherapy arm (cisplatin/pemetrexed in LUX-Lung 3 and cisplatin/gemcitabine in LUX-Lung 6).1
PFS in patients aged ≥65 years with common EGFR mutations (del19/L858R) in LUX-Lung 31
CI, confidence interval; Cis, cisplatin; HR, hazard ratio; Pem, pemetrexed; PFS, progression-free survival.
PFS in patients aged ≥65 years with common EGFR mutations (del19/L858R) in LUX-Lung 61
CI, confidence interval; Cis, cisplatin; Gem, gemcitabine; HR, hazard ratio; PFS, progression-free survival.
In exploratory analyses of LUX-Lung 7, there was a trend towards improved median PFS with afatinib versus gefitinib across all age groups analysed.1 OS with afatinib was generally consistent across age groups in LUX-Lung 7.1
OS by age group in LUX-Lung 71
CI, confidence interval; HR, hazard ratio; OS, overall survival.
Wu YL, et al. Clin Lung Cancer 2018;19(4):e465–79.
*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: January 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue